Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Creative Planning

Creative Planning raised its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 39.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,822 shares of the company’s stock after purchasing an additional 26,185 shares during the quarter. Creative Planning owned about 0.10% of Aquestive Therapeutics worth $462,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock valued at $128,000 after acquiring an additional 9,496 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $165,000. Blue Owl Capital Holdings LP raised its stake in shares of Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after acquiring an additional 265,000 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $76,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at approximately $380,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

AQST stock opened at $5.07 on Thursday. Aquestive Therapeutics, Inc. has a one year low of $1.55 and a one year high of $6.23. The stock has a market capitalization of $461.67 million, a PE ratio of -11.27 and a beta of 2.82. The company has a fifty day moving average of $4.91 and a 200-day moving average of $3.83.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period in the previous year, the business earned ($0.03) EPS. Equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Leerink Partners boosted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.